Ranolazine Tablet, Film Coated, Extended Release
Product Images NDC 69367-293

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 69367-293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ranolazine 01)

Chemical structure of ranolazine, displaying its molecular framework with key functional groups and ring systems characteristic of the compound.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

Label for Ranolazine Extended-Release Tablets 500 mg by Westminster Pharmaceuticals, LLC. The label states each tablet contains 500 mg Ranolazine, is for oral use, and packaging contains 60 film-coated extended-release tablets. It includes storage instructions and manufacturing details by ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (1000 mg Tablet Bottle Label)

Ranolazine Extended-Release Tablets label for 1000 mg strength. The film-coated, extended-release oral tablets are supplied in a package of 60. The label includes storage instructions and manufacturer information, indicating Westminster Pharmaceuticals, LLC as the labeler and ScieGen Pharmaceuticals, Inc. as the manufacturer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.